SKBR3

---

title: "SKBR3" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["human-cell-lines", "cancer-cell-lines", "breast-cancer-cell-lines", "breast-cancer"] description: "Human breast cancer cell line" topic_path: "general/human-cell-lines" source: "https://en.wikipedia.org/wiki/SKBR3" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Human breast cancer cell line ::

SkBr3 (also known as SK-BR-3) is a human breast cancer cell line isolated by the Memorial Sloan–Kettering Cancer Center in 1970 that is used in therapeutic research, especially in context of HER2 targeting.

History and characteristics

::figure[src="https://upload.wikimedia.org/wikipedia/commons/1/15/Trastuzumab_Fab-HER2_complex_1N8Z.png" caption="The HER2 gene product is over-expressed in SkBr3 cells"] ::

SkBr3 cells were derived from a pleural effusion due to an adenocarcinoma originating in a 43-year-old caucasian female. The cells are considered biosafety level 1. They are known to grow in grape-like clusters with an invasive phenotype resembling that of the cells in vivo.

Research applications

SkBr3 cells have been used in studies seeking to overcome Herceptin treatment resistance to HER2-overexpressing breast cancers. The cell line has also been examined for applications in CRISPR/Cas9 gene editing, antibody resistance in transfections, and HER2-based cancer therapies in context of microenvironment fluctuations.

References

References

1. "SK-BR-3: Human Breast Cancer Cell Line (ATCC HTB-30)". Memorial Sloan-Kettering Cancer Center.
2. "SK-BR-3 cells". Addex Bio.
3. (12 August 2011). "Choosing the right cell line for breast cancer research". Breast Cancer Research.
4. (November 2006). "Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor". Molecular Pharmacology.
5. (2 November 2016). "An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting". Nucleic Acids Research.
6. (1 July 2011). "HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment". Breast Cancer Research and Treatment.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::